Abbvie-Header Abbvie-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Y-Biologics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Creation of a Research Partnership Between Pierre Fabre and Y-Biologics to Develop New Immunotherapies Based on Monoclonal Antibodies

              Contact the Supplier

              Lead Product(s): Monoclonal antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 23, 2020

              Details:

              Under the terms of this agreement, Y-Biologics will contribute through its human antibody display platforms to generate therapeutic and diagnostic monoclonal antibodies directed against key molecular targets designated by Pierre Fabre.

              LegoChem Biosciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement

              Contact the Supplier

              Lead Product(s): Antibody drug conjugates

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Iksuda Therapeutics

              Deal Size: $407.3 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 16, 2020

              Details:

              The agreement grants Iksuda an access to Legochem Biosciences’ next-generation payload and proprietary linker to discover and advance lead ADC for difficult-to-treat tumours.

              PharmaCompass__DigitalAd